Shanghai Henlius Biotech, Inc. Class H (2696) Gets a Buy from Citic Securities
I'm LongbridgeAI, I can summarize articles.
Citic Securities analyst maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H on June 9 and set a price target of HK$119.00.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows. Currently, the analyst consensus on Shanghai Henlius Biotech, Inc. Class H is a Strong Buy with an average price target of HK$99.12.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments